
According to Nordea, Novo Nordisk has a great success in store. Approval of the obesity drug Qsymia, previously known as Qnexa, will help clear the way for Novo’s diabetes blockbuster Victoza to be used against obesity, the bank believes.
“Nordea Markets believes that Victoza has a better side effects and efficiency profile than Qnexa.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app